Process Cleaning Validation Master Plan V2-2
Process Cleaning Validation Master Plan V2-2
2, Effective Date: 28 Dec 2020 12:00 AM, Date of Next Review: 20 Dec 2024 3:26 PM
Approval: Approvers
Date Time Group Name
28-Dec-2020 09:18:24 AM MANAGEMENT Hamelburg, Crystal R
28-Dec-2020 09:31:50 AM QUALITY Baun, Cassie L
28-Dec-2020 09:39:08 AM DOC SPEC Gathagan, Danielle E
Notice: The Information contained herein is the property of BioSpectra and is Confidential.
TABLE OF CONTENTS
1. INTRODUCTION.......................................................................................................................................................... 3
2. RESPONSIBILITIES..................................................................................................................................................... 3
3. DEFINITIONS .............................................................................................................................................................. 5
4. REFERENCES .............................................................................................................................................................. 6
5. ACCEPTANCE CRITERIA DETERMINATION .......................................................................................................... 6
6. PROCESS CLEANING VALIDATION PROTOCOL ................................................................................................... 8
7. PROCESS CLEANING VALIDATION REPORT......................................................................................................... 8
8. REVALIDATION.......................................................................................................................................................... 9
9. ROUTINE CLEANING............................................................................................................................................... 10
10. HOLD TIMES............................................................................................................................................................. 10
Notice: The Information contained herein is the property of BioSpectra and is Confidential.
1. INTRODUCTION
The cleaning process developed by BioSpectra must conform to the FDA’s “Guide to
Inspections Validation of Cleaning Processes” (Inspection Guides, Validation of Cleaning Processes
(7/93), 2010) DCN:20-003647 and “APIC Guidance on Aspects of Cleaning Validation in Active
Pharmaceutical Ingredient Plants.” DCN:20-003596. In addition to ensuring that the FDA guidelines
are met, for each BioSpectra process that requires a cleaning process, BioSpectra will develop a set of
procedures that must be followed. In these procedures the cleaning process, sampling methods,
analytical testing methods and acceptance criteria will be defined.
The validation protocol will include the specific cleaning process, the exact sampling locations
and sampling methods, the length of time of the cleaning process, if applicable, any critical parameters
(for example, water source and purity, time, temperature, pressure, cleaning agents), acceptance
criteria to be documented and observed, as well as analytical tests.
The validation report will include all of the supporting documentation from the activities
performed for the validation protocol. This will include a conclusive statement of whether the cleaning
process has been validated and under what conditions it is considered a validated process. This will
also include a statement of waiting periods, both before and after cleaning.
All steps in the cleaning process validation will be documented. The documentation involved
in the validation process allows BioSpectra to demonstrate that the cleaning process is working as it is
intended to and that it has been tested and proven effective.
2. RESPONSIBILITIES
A validation team must be defined at the start of each validation study. This team should
consist of a representative member of the following departments including but not limited to:
appropriate member(s) of the Quality Unit, Manufacturing, and Management. If personnel from other
departments prove to be a resource to the validation process, then they should additionally be included
in the validation team.
The validation team is responsible for determining the parameters of the validation. This
should include: the validation methodology, the analytical methods used, the critical parameters that
need to be monitored, the acceptance criteria and the terms of revalidation. Once the validation
parameters have been established, it is the responsibility of the validation team to write the
validation/revalidation protocol.
Notice: The Information contained herein is the property of BioSpectra and is Confidential.
Notice: The Information contained herein is the property of BioSpectra and is Confidential.
chosen analytical method prove that the analytical method is capable of accurately detecting the
residue limit. Sampling locations and quantity of samples required will be determined by the
validation team based on the most representative locations within each piece of equipment. It is the
responsibility of the QC Manager or qualified personnel to review data collected from analysis that is
obtained from the validation. It is the responsibility of the QC Manager or qualified personnel to
develop any procedures regarding the analytical methods developed for or because of the validation.
It is the responsibility of the validation team to ensure that the guidelines in this Process
Cleaning Validation Master Plan are reflected in each individual cleaning validation protocol. The
Associate Director, Compliance or qualified personnel will be the lead of each validation team and
will schedule all validation meetings. It is the responsibility of the Associate Director, Compliance to
ensure that the validation follows cGMP guidelines. The QC Manager, Associate Director,
Compliance, and Executive Director of Manufacturing will ensure the validation is completed in a
timely fashion with all documentation correct and complete. It is the responsibility of the Associate
Director, Compliance to ensure that the protocol is approved by all appropriate parties prior to the start
of validation. The Associate Director, Compliance is responsible for all documentation related to the
validation. The validation team is responsible for any change control requirements that arise due to the
validation. It is also the responsibility of the Associate Director, Compliance to ensure that all
necessary protocols and documentation are completed by the end of the validation. This will ensure
that the validated procedures are followed the same way each time the cleaning process is required.
3. DEFINITIONS
! Validation Team: The Validation Team will consist of at least one member from each of
the following departments: Quality Unit, Manufacturing, and Management. There may be
instances where other departments are needed and personnel will be assigned from those
departments as needed.
! NOEL: No Observed Effect Level (Hall)
! ADI: Acceptable Daily Intake
! MACO: Maximum Allowable Carry Over
! EPA: Environmental Protection Agency
! Adulteration Limit: The limit calculated based on a 10 ppm carry over from product to
product
! Toxicological Limit: The limit calculated based on the LD50 of the products being cleaned
for
! LOD: Limit of Detection
! LOQ: Limit of Quantification
! Percent Recovery: Percentage of material able to be recovered during analysis
Notice: The Information contained herein is the property of BioSpectra and is Confidential.
! Clean Hold Time (CHT): The length of time equipment may remain idle and still be
considered clean
! Dirty Hold Time (DHT): The length of time the equipment may remain dirty and still be
able to be cleaned utilizing the standard validated cleaning method
! Routine Cleaning / Periodic: Cleaning performed using water only during or at the end of
a batch
! End of Campaign Cleaning: Cleaning performed using detergent (i.e.: CIP 100/150/200,
etc.) at the completion of a campaign or prior to product change-over
! After Maintenance Cleaning: A routine cleaning performed after maintenance personnel
have completed a preventative maintenance (PM) or work order (WO) unless specified
differently due to the work performed
! Visually Clean: The absence of visible residue on a surface
! Recovery Factor (RF): The percent recovery obtained during recovery studies for a
qualified individual who performs the swabs and rinses, as applicable
! Swab Solvent Volume (SSV): The volume of solvent used in the applicable vial where the
swab is placed for analysis of residues
! Swab Area (SA): The surface area of the swabbing area in in2 based on completed
recovery studies
! Rinse Volume (RV): The Final Rinse Volume using Water for Injection (WFI) or Purified
Water in Liters as detailed in the Cleaning Reference Sheet
! Rinse Area (RA): The sum of the rinse area for the equipment derived from the individual
surface areas listed in the respective Cleaning Reference Sheet
! Shared Surface Area (SSA)/Total Surface Area: The sum of the shared surface area of the
equipment derived from the individual surface areas listed in the respective Cleaning
Reference Sheet
4. REFERENCES
! BioSpectra Procedures:
o Analytical Methods Validation Master Plan
o Annual Product Reviews
o Cleaning Validation FMEA Template
o Cleaning Worksheet Procedure
o Discrepancy Investigation Procedure
o Equipment Qualification Master Plan
o QC Laboratory Investigation Procedure
! External References:
o Inspection Guides, Validation of Cleaning Processes (7/93). (2010, June 14).
o APIC Guidance on Aspects of Cleaning Validation in Active Pharmaceutical
Ingredient Plants
5. ACCEPTANCE CRITERIA DETERMINATION
Acceptance criteria will need to be determined prior to the start of the validation studies. The
acceptance criteria must be calculated in at least two different ways: Adulteration Limit and
Toxicology Limit, and should be calculated to show the MACO Limits, Individual Swab Limit
Printed On: 26-Oct-2021 03:50:16 PM Hosein, Amy : Printed By
Notice: The Information contained herein is the property of BioSpectra and is Confidential.
Calculations, and Individual Rinse Limit Calculations. The calculation that yields the lowest
specification for both product and detergent should be utilized to establish the respective acceptance
limits unless otherwise scientifically justified by the Validation Team. During Cleaning Validation
Protocol execution, the cleaning limits reference the worst-case minimum batch size listed in the
process room specific cleaning reference sheet.
Detergent ( )=
2)
( ℎ ( ( ))
The FDA requires that “The firm should challenge the analytical method in combination with
sampling methods used to show that contaminants can be recovered from the equipment surface and at
what level” (Nassani, 2006).
Utilizing all the information provided, the validation team must write the initial cleaning
validation protocol for the intended process/equipment. This protocol must be reviewed and approved
by all members of the validation team.
Notice: The Information contained herein is the property of BioSpectra and is Confidential.
The process cleaning validation protocol will include the following at a minimum: purpose,
scope, responsibilities, references, sampling method determination procedure, protocol execution, and
reporting.
Purpose: An introduction containing a brief description of the purpose and procedure of the
validation protocol will be written.
Scope: The scope should define the process to be evaluated and the limitations of the work
(Tunner). The scope should define at what location the procedure will be carried out and who in the
firm the procedure will effect.
Responsibilities: Defines the actions to be taken by the validation team members.
References: Will include current manufacturing process description, analytical method
determination procedure, cleaning method determination procedure, and manufacturing cleaning
procedure.
Sampling Method Determination Procedure: This section will detail what sampling is
required and how to perform swab sampling correctly.
Protocol Execution: Outlines the procedure for the execution of the cleaning validation during
product changeover or at the end of a campaign, cleaning activities, and cleaning verification between
batches within a campaign. Rinse samples will be collected during batches of a campaign, while
executing cleaning validation studies. These rinses will be monitored for product residues and
microbial residues, where applicable, and will be used for limit development, as applicable. Coverage
testing requirements, where applicable, will be detailed in the specific Cleaning Validation Protocol or
Spray Coverage Qualification Protocol prior to Cleaning Validation execution. If Coverage Testing is
unable to be completed, then the manufacturer of the equipment and Spray Ball will be referenced, as
it pertains to coverage details and space/square footage of equipment.
Reporting: Provides guidelines for issuance of the summary report.
The process cleaning validation report should be written after the protocol has been executed
and all data has been analyzed. “A final validation report is expected by the FDA” (Tunner). It is the
responsibility of the Associate Director, Compliance or qualified personnel, as detailed in the
respective Cleaning Validation Protocol, to write the report with support from the validation team and
the data obtained during the validation.
Notice: The Information contained herein is the property of BioSpectra and is Confidential.
The report should include a brief introduction of the scope of the validation, the time frame in
which it occurred, the cleaning procedure followed, methods used for analysis, and the lots of material
that were manufactured before the cleaning validation protocol was executed.
The Report must consist of an analysis of all data obtained during the validation. Data
obtained should be analyzed to ensure that the cleaning process is consistently meeting specifications.
If the process cannot consistently meet specifications, then the cleaning process should be considered
inadequate and re-evaluated. This re-evaluation will be considered the annual review.
Any Discrepancy Investigations that occurred during the validation must be documented
according to BioSpectra’s Discrepancy Investigation Procedure. The discrepancies must detail any
additional full validation runs that are required in order to validate that the corrective action was
sufficient (Tunner). Any Laboratory Investigations that occurred during the validation must be
documented according to BioSpectra’s QC Labroatory Investigation Procedure.
Finally, the report should contain a conclusion. The conclusion should be an overview of the
validation that was completed and under what circumstances the cleaning process is to be considered
validated. There must be a clear statement regarding the validation status of the cleaning process.
There must also be a clear statement of when the cleaning process is due for revalidation, as discussed
in Section 8.
8. REVALIDATION
Each cleaning process must have a documented review on an annual basis per Annual Product
Reviews DCN:16-000343. This review will allow the reviewers to determine whether revalidation is
necessary. This review should include a review of any pertinent change controls and any related
Laboratory Investigations or Discrepancy Investigations. This review should also include any
“cleaning failures or issues raised with the procedure and any minor changes to the procedure itself,
the cleaning facility, the equipment cleaned, or the soils encountered” (Tunner). Any major changes to
the cleaning process will require revalidation of the process. This review must be completed regardless
of whether a revalidation is required (Tunner). This review is only required after a validation has been
completed. It is not required to be created annually, while still in the validation process.
Notice: The Information contained herein is the property of BioSpectra and is Confidential.
9. ROUTINE CLEANING
For all products manufactured at BioSpectra facilities, a routine cleaning will be conducted
every ten batches (batch lot numbers are consecutive, if the lot number ends in “0” Manufacturing
performs a routine cleaning after the batch is manufactured) or at the end of a campaign for dedicated
process equipment. Routine cleaning can also be performed prior to ten batches on non-product
dedicated process equipment based on pre-validation studies and validation protocols. Routine
cleaning limits are established in the cleaning validation protocol. Routine cleaning will be conducted
with WFI or USP Purified Water only. No detergents will be used unless otherwise justified in the
cleaning verification portion of the cleaning validation protocol. If after ten batches, all acceptance
criteria are met during the routine cleaning, then the campaign count will be reset to one. If routine
cleaning fails to meet established acceptance criteria, then the equipment in question must be cleaned
utilizing detergent in order to reset the campaign count to one. The campaign count should not exceed
ten batches before routine cleaning has been executed.
The period and when appropriate, conditions of storage of equipment before cleaning,
commonly referred to as dirty hold time (DHT) and the time between cleaning and equipment reuse,
prior to additional cleaning, commonly referred to as clean hold time (CHT), should form part of the
validation of cleaning procedures. This is to provide confidence that routine cleaning and storage of
equipment does not allow potential for buildup of degradation products that may not be removed by
the standard cleaning procedure and does not allow for the possibility of microbial contamination of
equipment, and to ensure that these possible risks are properly assessed and controlled. These times
will be determined based on process risk assessments and/or at the completion of the cleaning
validation study. The timeframe of 10 days for Clean Hold Time studies and 48 hours to visually clean
for Dirty Hold Time is required at minimum.
Notice: The Information contained herein is the property of BioSpectra and is Confidential.